ET743 also inhibits FUS-CHOP transcription factor binding to the promoters of different genes among CHOP, pentraxin 3 and fibronectin 1 to restore adipogenic differentiation in myxoid liposarcoma, a cancer against which ET743 entered into phase I/II clinical trials [262,263,264,265]. Here, FUS is linked to cancer.